Revenue Misses Trigger Sharp Sell-Offs for Zevia and Chemed in Q4 Earnings
Key Takeaways
- Zevia and Chemed both reported fourth-quarter revenue that fell short of analyst expectations, leading to significant stock price declines.
- While Zevia managed a slight EPS beat, Chemed saw a dramatic 14.7% plunge as investors prioritized top-line growth and guidance over narrow margin improvements.
Mentioned
Key Intelligence
Key Facts
- 1Zevia reported Q4 revenue of $37.87M, missing analyst estimates by $2.26M.
- 2Zevia's GAAP EPS of -$0.02 beat consensus expectations by $0.01.
- 3Chemed Corporation stock plummeted 14.7% following its Q4 earnings release.
- 4Both companies reported sales figures below Wall Street estimates on Feb 25, 2026.
- 5The sharp decline in Chemed shares reflects heightened volatility in the healthcare and residential service sectors.
| Metric | ||
|---|---|---|
| Revenue Performance | Missed by $2.26M | Below Estimates |
| EPS Performance | Beat by $0.01 | Not Disclosed |
| Stock Reaction | Negative | -14.7% Drop |
| Primary Sector | Consumer Beverages | Healthcare/Services |
Analysis
The fourth-quarter earnings season for 2025 has revealed a heightened sensitivity among investors toward revenue growth, as evidenced by the sharp market reactions to misses from Zevia PBC (ZVIA) and Chemed Corporation (CHE). On February 25, 2026, both companies reported top-line figures that failed to meet Wall Street's consensus, triggering immediate sell-offs that underscore a broader market shift. Investors are increasingly penalizing companies that cannot sustain revenue momentum, even when bottom-line performance remains relatively stable or shows marginal improvement.
Zevia PBC, the zero-calorie beverage maker, reported revenue of $37.87 million for the quarter, missing analyst estimates by approximately $2.26 million. Despite this top-line disappointment, the company actually outperformed on earnings per share (EPS), reporting a GAAP loss of $0.02, which was $0.01 better than the anticipated loss of $0.03. This dynamic—a revenue miss paired with an EPS beat—typically suggests that management is successfully controlling costs or optimizing margins, but in the current high-growth consumer goods environment, the market's focus remained squarely on the lack of sales volume. The miss suggests that Zevia may be facing stiffer competition in the natural soda category or experiencing a slowdown in retail velocity as consumers tighten discretionary spending.
Despite this top-line disappointment, the company actually outperformed on earnings per share (EPS), reporting a GAAP loss of $0.02, which was $0.01 better than the anticipated loss of $0.03.
In contrast, the reaction to Chemed Corporation's results was significantly more severe. Chemed, which operates the VITAS Healthcare hospice business and the Roto-Rooter plumbing service, saw its stock price crater by 14.7% following its revenue miss. For a diversified service company like Chemed, a nearly 15% single-day drop is an outlier that points to deeper concerns regarding labor costs in the healthcare sector or a cooling of residential service demand. Chemed has historically been a steady performer, but the scale of this decline suggests that the revenue shortfall may have been accompanied by cautious forward-looking guidance or a structural shift in its core VITAS segment, which has been grappling with nursing shortages and regulatory reimbursement changes.
What to Watch
When comparing the two, the market's reaction to Chemed highlights the vulnerability of high-multiple service stocks to even minor growth hiccups. While Zevia is a smaller, more volatile consumer play, Chemed is often viewed as a defensive staple. The fact that both were punished simultaneously indicates that the 'earnings quality' bar has been raised for 2026. Analysts are now looking beyond cost-cutting measures and focusing on whether these companies can expand their market share in an environment where inflation has moderated but interest rates remain a persistent headwind for expansion.
Looking ahead, the divergence between Zevia's cost-efficiency (the EPS beat) and its sales struggle will be the primary narrative for its upcoming fiscal year. For Chemed, the focus will shift to its March investor calls to determine if the 14.7% drop was an overreaction or a necessary correction based on a revised growth trajectory for VITAS. Investors should watch for whether these revenue misses are isolated incidents or indicative of a broader trend where consumer and service-oriented firms are hitting a ceiling on pricing power, forcing them to rely on volume growth that is becoming harder to secure.
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |